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Objective: The radial artery is increasingly used for coronary artery bypass grafts, but
its potential for spasm increases postoperative risk. Alpha-calcitonin gene–related
peptide is a potent antihypertensive peptide.
Thus, we set out to determine whether calcitonin gene–related peptide can impair
angiotensin II–mediated vasoconstriction in human radial arteries and, if so, to deter-
mine its mechanism of action.
Methods: Radial arteries were placed in organ bath chambers and preincubated with
1029 to 1027 mol/L alpha-calcitonin gene–related peptide for 20 minutes before
initiating an angiotensin II dose response curve (10210–1026 mol/L).
Results: Calcitonin gene–related peptide, 1027, 1028, 33 1029, and 1029 mol/L, re-
duced angiotensin II–mediated vasoconstriction to 30.5%6 7.2% (P, .001), 32.2%
6 11.7% (P , .001), 62.6% 6 8.4% (P , .001), and 77.6% 6 6.7% (P , .01),
respectively, compared with control (normalized to 100%). Calcitonin gene–related
peptide also significantly decreased basal vascular tension in human radial arteries
(P , .05 in all cases). N-nitro-L-arginine methyl ester, 4-aminopyridine, charybdo-
toxin, and apamin had no effect on calcitonin gene–related peptide relaxation, but
Ba21 impaired the effects of alpha-calcitonin gene–related peptide.
Conclusions: Alpha-calcitonin gene–related peptide dose dependently impaired an-
giotensin II–mediated vasoconstriction in human radial arteries, independent of nitric
oxide and all potassium channels except the barium-sensitive Kir channel. Thus, cal-
citonin gene–related peptide is an endogenous inhibitor of angiotensin II–mediated
vasocontriction in the human radial artery.
R
adial arteries are being used more frequently as coronary artery bypass grafts.
However, radial arteries are prone to spasm and thus increase the risk of graft
failure.1 Angiotensin II (ang II) is an active component of the renin–angioten-
sin system, which, through its receptor (AT1R), plays an important role in the control
of vasoconstriction, cell growth and apoptosis, cell migration, and extracelluar matrix
deposition, events that are involved in cardiovascular disease.2 On the other hand,
calcitonin gene–related peptide (CGRP) is an inhibitor of cell growth and a potent en-
dothelium-independent vasodilator,3-5 thus suggesting that it could inhibit ang II–me-
diated effects. Indeed, long-term ang II infusion is accompanied by an increase in
CGRP receptor expression in mesenteric arteries but not in CGRP levels in plasma.6
aCGRP is a 37-amino acid peptide, produced by tissue-specific alternative splicing of
the primary transcript of the calcitonin/aCGRP gene.7 A second CGRP isoform,
ßCGRP, is encoded by a different gene locus and is localized almost exclusively to
specific neuronal sites.8 These two CGRP isoforms—a and b in rats and I and II in
humans—exhibit overlapping biological activities in most vascular beds,9 but
aCGRP appears to be regulated by nitric oxide (NO).10 CGRP has complex cardio-
vascular actions. For example, the intramuscular gene transfer of CGRP inhibits neo-
intimal hyperplasia after balloon injury in the rat abdominal aorta,11 possibly by
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PAbbreviations and Acronyms
ang II 5 angiotension II
CGRP 5 calcitonin gene–related peptide
EDHF 5 endothelium-dependent hyperpolarization
L-NAME 5 N-nitro-L-arginine methyl ester
NO 5 nitric oxide
affecting the NO system10,11 and the proliferation of vascular
smooth muscle cells induced by fetal bovine serum.12 More
important, CGRP can act directly on smooth muscle cells
and stimulate relaxation independently of endothelial func-
tion in porcine coronary arteries.3Inasmuch as CGRP can in-
duce vasorelaxation independently of endothelial function
and CGRP appears to counteract ang II vasoconstriction in
animal models, we sought to determine whether such effects
extend to human arteries. To this end, we have used human
radial arteries with impaired endothelial function to test the
direct effects of CGRP on ang II–mediated vasoconstriction.
Methods
Discarded distal segments of radial arteries13 were obtained from 25
patients undergoing coronary artery bypass grafting using the
‘‘open’’ technique for harvesting. Patients aged 48 to 70 years
gave informed consent and were receiving 3-hydroxy-3-methylglu-
taryl coenzyme A reductase inhibitors, angiotensin-converting
enzyme inhibitors, nitrates, and beta adreno-receptor blockers.
Patients receiving angiotensin receptor blockers were excluded
from this study. Only nontraumatized vessel segments were used
in this study. This study was approved by the Austin Hospital Med-
ical Research Ethics Committee and followed institutional guide-
lines. Harvesting was performed by techniques previously
established in our operating theaters1; in particular, the specimens
were obtained after intraluminal hydrostatic dilatation with papaver-
ine, which impairs endothelial function.
Isometric Tension Studies
Blood vessels were cleaned of connective tissue and fat and stored at
4C overnight. Pilot studies in our laboratory show no difference in
vessel function between freshly isolated radial artery rings and those
kept in overnight 4C storage, as also described elsewhere.14
Vessels were then cut into 3-mm rings and sequentially mounted
between two metal hooks in organ baths attached to force
displacement transducers (Grass FT03; Grass Instrument Co,
Quincy, Mass). The baths were filled with Krebs solution, kept at
a constant temperature of 37C, and continuously bubbled with
95% oxygen/5% carbon dioxide. After a 2-hour equilibration pe-
riod, the rings were stretched to their optimized tension. This tech-
nique allows normalization of vascular rings to a physiologic
pressure in vitro compared with in vivo and is the accepted method
for isometric tension studies.15,16 After another 2-hour equilibration
period, Krebs buffer was replaced with high potassium solution
(KPSS, 124 mmol/L K1) to induce maximal constriction. After
the rings reached plateau (approximately 8 minutes), the rings
were flushed with Krebs solution. After another 2-hour equilibrationThe Journal of Thoperiod, rings were incubated with 1029 to 1027 mol/L aCGRP17 20
minutes before the initiation of an ang II dose response curve
(10210–1026). The vessel equilibration time also served to minimize
the effect of patient therapy on vessels.18 All experimental data were
normalized to control, which was set at 100%.
To determine the influence of potassium channels or NO on the
inhibitory effects of CGRP, N-nitro-L-arginine methyl ester (L-
NAME; 1025 mol/L, to inhibit NO), 4-aminopyridine (3 mmol/L,
to inhibit voltage-dependent K1 channels), charybdotoxin and apa-
min (503 1029 mol/L and 33 1027 mol/L, respectively), to inhibit
endothelium-dependent hyperpolarization (EDHF), and calcium-ac-
tivated K1 channels and 1024 mol/L barium chloride (to inhibit in-
wardly rectifying K1 channels) where used. These concentrations
have been shown to be specific for each potassium channel.19,20
Data Analysis
Data are presented as mean6 standard error of the mean, where ‘‘n’’
represents the number of independent samples studied. Data from
arterial samples are expressed as percent response to 124 mmol/L
KCl. Statistical comparisons were undertaken with either the
Student t test or a 1-way analysis of variance (where appropriate)
and a P value of .05 using GraphPad Prism software (GraphPad
Software, Inc, San Diego, Calif).
Results
Effects of aCGRP on Ang II–mediated
Vasoconstriction
aCGRP potently inhibited ang II–mediated vasoconstriction
at all concentrations used. Both 1027 mol/L and 1028 mol/L
aCGRP inhibited maximal contraction evoked by 1026 mol/L
ang II by 69% (P, .001) and 68% (P, .001), respectively.
Indeed, 1027 mol/L aCGRP inhibited ang II–mediated
vasoconstriction from 3 3 10210 mol/L [ang II], reducing
constriction from 1.56% 6 0.45% to 20.62% 6 0.41%
(P, .05). The negative value indicates continued relaxation
rather than constriction as seen with the control. The inhibi-
tory effect of 1027 mol/L aCGRP continued to 1029 mol/L
ang II, reducing constriction from 4.4% 6 1% to 0.08% 6
0.65% (P , .05). Starting at the lowest concentration of
1029 mol/L ang II, aCGRP concentrations of 3 3 1029,
1028, and 1027 mol/L all significantly inhibited ang II–medi-
ated vasoconstriction. At a concentration of 1029 mol/L,
aCGRP inhibited ang II–mediated vasoconstriction only at
the concentration of 3 3 1026 mol/L, by 21% (P , .05)
and at the maximal ang II concentration used, 1026 mol/L
by 22% (P , .01) (Figure 1, A). There was no difference in
maximum contraction evoked by 124 mmol/L potassium
between groups (Figure 1, B).
Effects of aCGRP on Basal Tone
aCGRP also significantly decreased basal vascular tension in
human radial arteries. After the 20-minute period following
the addition of aCGRP or vehicle (control), 1027 mol/L
aCGRP showed the highest decrease in basal tension (ex-
pressed as force in grams, Figure 1, C) compared withracic and Cardiovascular Surgery c Volume 136, Number 2 371
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Figure 1. Graph showing the inhibitory
effects of CGRP on angiotensin II–medi-
ated vasoconstriction. A, CGRP concen-
trations of 1028 mol/L (n 5 5) and 1027
mol/L (n 5 9), inhibition of angiotensin
II remained constant at 68% and 69%,
respectively, and did not follow the
dose-dependent increase observed for
lower concentrations (P < .001 in both
cases). B, Box plots showing the maxi-
mum potassium (K1) constriction per
CGRP dose tested. Each experimental
dose (closed box) was normalized to
its adjacent segment (control, open
box), as to restrict variation between
segments. There was no difference in
the maximum contraction to 124 mmol/
L potassium in any group. C, Exposing
human radial arteries to increasing
concentrations of CGRP has a dose-de-
pendent, albeit slight, dilatory effect on
the basal arterial tone of isolated hu-
man radial arteries over a 20-minute pe-
riod. Results are mean6 SEM, *P< .05,
**P < .01, yP < .001.control:20.646 0.2 g versus 0.116 0.03 g (P, .001). This
was followed by 1028 mol/L aCGRP (20.376 0.03 g; P,
.05), 3 3 1029 mol/L (20.19 6 0.08 g; P , .05), and 1029
mol/L aCGRP (20.16 6 0.12 g; P , .05).
Effects of L-NAME on aCGRP-induced Vasodilation
To determine whether NO release was involved in the effects
of CGRP, we added L-NAME to the organ baths 20 minutes
before the ang II dose response curve. Then, at 1028 mol/L
(ang II), aCGRP (1028 mol/L) was added and aCGRP com-
pletely relaxed arteries after approximately 10 minutes. The
actual trace is shown in Figure 2, A, and the results of 3 inde-
pendent experiments are shown in Figure 2, B.
Effects of aCGRP on Potassium Channels
To determine whether potassium channels were involved in
the effects of aCGRP, we added 4-aminopyridine to the ra-
dial artery and vasoconstriction occurred rapidly, an effect
that was completely reversed by the addition of 1028 mol/L
aCGRP but restored by the addition of ba21 (actual trace
shown, Figure 2, C); the results of 5 independent experiments
are shown in Figure 2, D. As well, charybdotoxin plus apa-
min (Figure 2, E and F)) was added to radial arteries to inhibit
endothelium hyperpolarization via the release of EDHF and
calcium-activated K1 channels. This had no effect on 1028
mol/L aCGRP-induced reduction in basal tension, but
Ba21 impaired CGRP effects and induced potent vasocon-
striction (actual trace shown, Figure 2, E). The results of 3 in-372 The Journal of Thoracic and Cardiovascular Surgery c Audependent experiments are shown in Figure 2, F. Moreover,
the addition of Ba21 to radial arteries per se induced vasocon-
striction, but the addition of 1028 mol/L aCGRP had no
effect (actual trace shown, Figure 2, G). The results of 3
independent experiments are shown in Figure 2, H.
Discussion
This study clearly establishes the importance of aCGRP in
influencing radial artery basal tone and desensitizing it to
the vasoconstrictive effects of ang II. Furthermore, it was
demonstrated that aCGRP-induced vasodilation is preserved
in the presence of L-NAME, an NO synthase inhibitor, sug-
gesting that aCGRP is not dependent on NO for its activity,
but could be associated with opening the Kir potassium chan-
nel. We further propose that aCGRP at a concentration of 10
nmol/L could be used in preoperative radial artery bath prep-
arations to impair vasospasm and improve postoperative risk.
Growing evidence is indicating that aCGRP and ang II
may act reciprocally to help maintain circulatory homeosta-
sis.21-25 Our results support this hypothesis, indicating that
CGRP acts as a functional antagonist of ang II–mediated
vasoconstriction and attenuates vasoconstriction in a dose-
dependent manner. This result is consistent with previous
rat model investigations, which found that CGRP inhibits
ang II–induced vasoconstriction.21,22 Indeed, the only other
comparable study involving human radial arteries also
yielded similar results.26gust 2008
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PFigure 2. A, Actual trace showing the
effects of 1028 mol/L CGRP on ang II–in-
duced vasoconstriction in the presence
of 1025 mol/L L-NAME. CGRP potently
restores normal basal tension after ap-
proximately 10 minutes, indicating no
effect of nitric oxide on CGRP-induced
vasodilation. B, Tabulated results of 3
independent experiments. C, 4-Amino-
pyridine (4-Ap) was used to block
voltage-dependent K1 channels, and
vasoconstriction occurred immediately
after the addition of the drug. CGRP
was able to restore basal tensionwithin
minutes, but 1024 mol/L Ba21 (Kir inhib-
itor) caused marked vasoconstriction
even in the presence of CGRP. D, Tabu-
lated results of 5 independent experi-
ments. E, Charybdotoxin plus apamin
(Ch1Ap) was added concomitantly to
radial arteries to inhibit EDHF and
Ca21-activated K1 channels. As shown,
1028 mol/L CGRP was able to relax the
artery below basal tension, but 1024
mol/L Ba21 (Kir inhibitor) caused
marked vasoconstriction even in the
presence of CGRP. F, Tabulated results
of 3 independent experiments. G, The
addition of 1024 mol/L Ba21 to radial ar-
teries caused marked vasoconstriction
that was not able to be returned to base-
line by the addition of 1028 mol/L CGRP,
indicating CGRP could act via the
Kir channel. H, Tabulated results of 4
independent experiments. Results are
mean 6 SEM, *P < .05.Altered vascular K1 channel function in cardiovascular
disease could be either a cause or consequence of the disease.
A current review by Sobey20 clearly describes the role of K1
channels in cardiovascular disease. Nevertheless, studies
have indicated that current medications used in the treatment
of hypertension may already inadvertently involve CGRP and
thus open K1 channels. Qin and associates27 demonstrated
that the depressor effects of losartan (ang II receptor antago-
nist) and perindopril (angiotensin-converting enzyme inhibi-
tor) may be partially mediated via increased synthesis and
release of CGRP. Furthermore, the antihypertensive effect
of the novel drug rutaercarpine may also be mediated by stim-
ulation of CGRP synthesis and release.28 Rutaecarpine is
a quinazolinocarboline alkaloid isolated from a widely known
Chinese herbal drug Wu-chu-yu. In animal models, its mode
of action is suggested to be via stimulating endogenous
CGRP release via activation of vanilloid receptor subtype
1.28,29 Whether rutaecarpine causes similar effects as CGRP
in human radial arteries is the focus of ongoing studies.The Journal of ThoThe precise mechanisms that regulate the expression and
release of CGRP are unknown. However, several different
classes of regulatory factors act to modulate CGRP synthesis
and release by antagonizing or activating nerve growth fac-
tor.30 As CGRP is released directly onto the smooth muscle
cell layer from the innervation into the wall, the physiologic
concentration of CGRP at the site of action is many times
greater than the picomolar plasma concentration observed
in healthy human volunteers.31 It is generally considered
that the levels of CGRP detected in plasma are likely to be
due to leakage after localized release rather than a specific
systemic function. As well, although CGRP is widely estab-
lished as a potent vasodilator, its exact mechanism of action
remains unclear. There are currently two modes of action, en-
dothelium dependent and endothelium independent.32 The
endothelium-dependent pathway suggests that CGRP activ-
ity is mediated via the production of endothelial NO, which
then relaxes vascular smooth muscle cells.32 The endothe-
lium-independent pathway proposes that CGRP directlyracic and Cardiovascular Surgery c Volume 136, Number 2 373
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CSPbinds to receptors on the smooth muscle cells and is coupled
to production of cyclic adenosine monophosphate by adeny-
late cyclase. The increase in intracellular cyclic adenosine
monophosphate concentration stimulates protein kinase A,
and this opens K1 channels and activates calcium sequestra-
tion mechanisms to cause smooth muscle cell relaxation.32
The majority of data from studies involving rat, human,
and porcine tissues suggest that CGRP can cause vasodila-
tion in the absence of an endothelium, thereby supporting
the role of an endothelium-independent pathway.32,33 Con-
versely, studies have also shown that NO synthase inhibitor
blocks CGRP activity in the rat aorta, rat pulmonary artery,
and human internal thoracic artery, suggesting CGRP-medi-
ated vasodilation is dependent on the presence of NO and
therefore the endothelium.34-36 In our study, blocking NO
synthesis with L-NAME, a NO synthase inhibitor, did not af-
fect CGRP-induced vasodilation, suggesting that CGRP is
able to act via a pathway independent of the endothelium
or NO. Therefore, this result supports the notion that in hu-
man radial arteries, CGRP activity might be mediated by
an endothelium-independent pathway. It is difficult to specu-
late as to why the internal thoracic artery and radial artery re-
spond differently to CGRP, although it could be associated
with the increased wall thickness and intimal thickening of
radial arteries.1 However, we show clear evidence that
CGRP can induce vasodilation in the presence of calcium-ac-
tivated K1 channel blockade, voltage-dependent K1 channel
blockade, but not with inwardly rectifying K1 channel block-
ade (Kir), suggesting that a possible mechanism of action for
CGRP is by opening the Kir channel. Our data suggest that
the development of potassium channel openers could be
a new avenue for the treatment of radial arteries before by-
pass surgery to impair spasm and lessen postoperative risk.
Furthermore, the radial arteries used in this study did not
respond to acetylcholine-mediated vasodilation (results
not shown), indicating that a functional endothelium is not
necessary for CGRP function.
In conclusion, this study has demonstrated that CGRP de-
creased the basal arterial tone in human radial arteries and,
when challenged with ang II, CGRP significantly inhibited
ang II–induced vasoconstriction in a dose-dependent manner.
Inhibition of the Kir channel completely impaired the effects
of CGRP, indicating an endothelium-independent mecha-
nism for the actions of CGRP and is thus possibly more effec-
tive in diseased human vessels with underlying endothelial
dysfunction.
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